Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

BACKGROUND: Enfortumab vedotin (EV) is an antibody‐drug conjugate showing significant overall survival (OS) benefit versus chemotherapy for patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC) in EV‐301. This subgroup analysis was conducted to further analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Nobuaki, Yonese, Junji, Kojima, Takahiro, Azuma, Haruhito, Matsumoto, Hiroaki, Powles, Thomas, Rosenberg, Jonathan E., Petrylak, Daniel P., Matsangou, Maria, Wu, Chunzhang, Campbell, Mary, Yamashiro, Mayumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939146/
https://www.ncbi.nlm.nih.gov/pubmed/36052536
http://dx.doi.org/10.1002/cam4.5165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939146/
https://www.ncbi.nlm.nih.gov/pubmed/36052536
http://dx.doi.org/10.1002/cam4.5165

Ejemplares similares